Bravecto is a drug owned by INTERVET, INC. It is protected by 19 US drug patents filed from 2025 to 2035. Out of these, 9 patents are active and 10 patents have expired. Details of Bravecto’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US11285101 | 03 Apr, 2033 | Active |
| US11285101 | 03 Apr, 2033 | Active |
| US9173870 | 22 Dec, 2031 | Active |
| US9532978 | 22 Dec, 2031 | Active |
| US7662972 | 28 Jun, 2027 | Active |
| US7662972 | 28 Jun, 2027 | Active |
| US7662972 | 28 Jun, 2027 | Active |
| US8492311 | 04 Mar, 2025 | Expired |
| US8492311 | 04 Mar, 2025 | Expired |
| US8492311 | 04 Mar, 2025 | Expired |
| US10045969 | 04 Mar, 2025 | Expired |
| US10045969 | 04 Mar, 2025 | Expired |
| US10596157 | 04 Mar, 2025 | Expired |
| US10596157 | 04 Mar, 2025 | Expired |
| US8022089 | 04 Mar, 2025 | Expired |
| US8022089 | 04 Mar, 2025 | Expired |
| US8022089 | 04 Mar, 2025 | Expired |
Exclusivity Information
Bravecto holds 2 exclusivitys out of which 2 have expired. Details of Bravecto's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Aug 09, 2025 |
| NCE | May 15, 2019 |
About Bravecto
Bravecto is a drug
owned by INTERVET, INC.
Bravecto uses
Fluralaner as the active
ingredient.
Active Ingredient:
Bravecto uses
Fluralaner as the active ingredient.
Check out other Drugs and Companies using
Fluralaner ingredient.